Get the Stockscreener App
0.9663
10.22%
-0.1037
Rani Therapeutics Holdings Inc stock is traded at $0.9663, with a volume of 1.46M.
It is down -10.22% in the last 24 hours and up +2.31% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$1.07
Open:
$0.9889
24h Volume:
1.46M
Relative Volume:
1.34
Market Cap:
$96.55M
Revenue:
$1.63M
Net Income/Loss:
$-40.95M
P/E Ratio:
-1.6464
EPS:
-0.5869
Net Cash Flow:
$-18.80M
1W Performance:
+8.62%
1M Performance:
+2.31%
6M Performance:
-40.70%
1Y Performance:
+55.74%
1-Day Range:
$0.92
$0.9894
1-Week Range:
$0.8901
$1.12
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.9663 | 106.91M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
437.06 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.52 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.40 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.90 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.97 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics to raise $20M in registered direct offering - MSN
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice - TipRanks
Rani Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RANI: Q1 2026 saw clinical progress, leadership changes, and a reduced net loss year-over-year - TradingView
Rani Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Rani Therapeutics (RANI) posts Q1 2026 loss with new Chugai revenue and $43M cash - Stock Titan
Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition - Stock Titan
Oral biologics firm Rani trims Q1 loss; CFO to step down - Stock Titan
Rani Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
SymBiosis Capital holds 4.43M RANI shares, reports 4.4% stake (RANI) - Stock Titan
TradingKey - TradingKey
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - The Manila Times
Rani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
MSN Money - MSN
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday - MarketBeat
RANI Technical Analysis | Trend, Signals & Chart Patterns | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):